Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry.

J Arrhythm · 2025 · PMC11730714 · PMID 39817026

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

6 A decreasing trend in the incidence rates of CV and bleeding events was noticeable in this two‐year outcome of the Taiwanese population, affirming the enduring effectiveness and safety of edoxaban over 2 years in a real‐world setting.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.